Sarepta Therapeutics' licensing partner Arrowhead Pharmaceuticals said on Wednesday it expects to receive near-term milestone ...

Arrowhead plans to seek regulatory clearance in late 2024 to begin clinical trials. In obese and diabetic mice, INHBE siRNA reduced INHBE mRNA expression by 95%, body weight by 19% and fat mass by ...

Arrowhead Pharma Stock Soars Pre-Market On $825M Sarepta Licensing Deal: Retail Activity Hits Year-High© Stocktwits Arrowhead Pharmaceuticals Sentiment and Message Volume on Nov 26 as of 8:05 a.m ...

On Monday, Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) released topline results from the Phase 3 PALISADE study of plozasiran in patients with genetically confirmed or clinically diagnosed ...